Wegovy vs Zepbound
Canada's two weight-management-labelled injections, side by side.
| Attribute | Wegovy | Zepbound |
|---|---|---|
| Molecule | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Frequency | Once weekly injection | Once weekly injection |
| Format | Prefilled single-dose pen | Prefilled single-dose pen |
| Monthly price (CAD) | $400–570/mo, $540–570 at maintenance dose | $435–550/mo by dose |
| Approval / indication in Canada | Chronic weight management | Chronic weight management |
| Availability | Widely stocked, most pharmacies | Approved May 2025, availability expanding |
The two purpose-built weight-management drugs
Wegovy and Zepbound are the only two GLP-1-class injections currently approved in Canada specifically for chronic weight management rather than for diabetes, which puts them in direct competition for the same patient population. Wegovy, Novo Nordisk's semaglutide product, has been available in Canada longer. Zepbound, Eli Lilly's tirzepatide product, received Health Canada approval in May 2025 and is still expanding its retail footprint, so availability at a given pharmacy is worth confirming before a prescription is written.
The underlying molecules differ the same way they do in the Ozempic-versus-Mounjaro comparison: Wegovy acts on a single hormonal pathway, Zepbound acts on two. That mechanistic difference is the same one driving the general trend in trial data toward a larger average weight-loss effect with tirzepatide-based products, though as with any average, individual outcomes vary.
Pricing and the coverage wall both drugs share
Monthly pricing lands in a similar range for both — Wegovy from roughly $400 up to $570 at its maintenance dose, Zepbound from about $435 to $550 depending on dose tier. Neither has a meaningful price advantage over the other once a patient reaches a typical maintenance dose, so cost alone rarely settles the decision between them.
What both share, and what tends to matter more than the modest price gap between them, is the coverage landscape. No provincial public drug plan in Canada currently reimburses a GLP-1 medication for weight management alone — that coverage exists only for diabetes-labelled indications. On the private side, roughly 31% of employer plans extend some coverage to weight-management GLP-1s, and even where coverage exists, annual maximums or prior-authorization requirements can leave a significant balance for the patient to cover directly.
Manufacturer savings programs
Both Novo Nordisk and Eli Lilly run savings programs that can reduce the out-of-pocket cost for eligible patients, particularly those with private insurance that only partially covers the drug. The value of these programs varies by plan type and eligibility criteria, and they're worth asking about directly rather than assuming the list price is the final number — for many patients it isn't.
How generic entry may reshape this comparison
Neither Wegovy nor Zepbound has a direct generic equivalent on the Canadian market yet in the way Ozempic now does, but the ground is shifting underneath both. Novo Nordisk's semaglutide data exclusivity expired in January 2026, and Health Canada approved Sevmia, the first generic referencing Wegovy specifically, in June 2026 — pricing for it hadn't been widely published as this comparison was written, but the general expectation is that it will undercut Wegovy's brand price once fully available, the same way generic semaglutide has already undercut Ozempic. Zepbound, protected by its own more recent tirzepatide patents, doesn't yet face the same competitive pressure, which means the price relationship between these two drugs could look meaningfully different a year from now than it does today.
The verdict: questions to ask your doctor
Because both drugs sit in roughly the same price band and the same uncovered-by-default category, the more useful line of questioning for a doctor is clinical rather than financial: which mechanism, single-pathway or dual-pathway, makes more sense given your health history and any other medications you're on.
Ask specifically whether your employer plan's weight-management coverage, if you have any, applies equally to both drugs or favours one — some private formularies list one product preferentially, which can make an otherwise close price comparison lopsided in practice.
It's also worth asking about the manufacturer savings program for each drug before assuming the sticker price is what you'll actually pay, since eligibility and savings amounts differ between Novo Nordisk's and Eli Lilly's programs and can meaningfully change the real monthly cost.
Given that a generic referencing Wegovy has just been approved and pricing is still settling, it's reasonable to ask your pharmacist whether a lower-cost semaglutide option has become available since your last fill, particularly if cost is the main factor tipping you toward one drug over the other.
Frequently asked
- Is Zepbound available everywhere in Canada yet?
- Zepbound was approved by Health Canada in May 2025 and availability has been expanding since, but stock at a specific pharmacy isn't guaranteed the way it is for a longer-established product like Wegovy. It's worth calling ahead before assuming it's on the shelf.
- Is Zepbound cheaper than Wegovy?
- The two land in a similar monthly range, roughly $400–570 for Wegovy and $435–550 for Zepbound depending on dose, so neither has a clear, consistent price advantage over the other.
- Does insurance cover either drug for weight loss?
- No provincial public plan covers a GLP-1 for weight management alone in Canada. About 31% of employer private plans include some coverage for this indication, so it comes down to your specific benefits plan.